This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ920C6_L.jpg
Lilly has offered $12.50 per Point Biopharma share held, representing a premium of about 87% to the stock’s last close.
Point Biopharma’s shares soared 84% in premarket trading.
The companies expect the deal to close by the end of 2023.
